Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazufloxacin Mesilate Ear Drops in Otitis Media
NCT02592096Phase 1Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Jul 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of pazufloxacin in otitis media (4 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoint: Safety and tolerance of pazufloxacin mesilate ear drops at 24 hours. Status: unknown.
02
Drugs
pazufloxacin
03
Conditions
otitis media
Beyond the preview
Go deeper on NCT02592096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592096.